Journal
BRAIN RESEARCH BULLETIN
Volume 172, Issue -, Pages 229-235Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.brainresbull.2021.05.001
Keywords
Epilepsy; Status epilepticus; Seizure; Inflammation; NLRP1 inflammasome; NLRP3 inflammasome
Categories
Ask authors/readers for more resources
Inflammation plays a role in the progression and pathogenesis of epilepsy, with the inflammasome being a key player in this process. NLRP1 and NLRP3, two well-characterized members of the inflammasome, have been reported to be activated in epilepsy, highlighting their significance in epilepsy research.
Epilepsy is one of the most prevalent serious brain disorders worldwide. Accumulating evidence has suggested that inflammation participates in the progression and pathogenesis of epilepsy. During inflammation, a cytosolic multimolecular complex called the inflammasome is activated, driving the innate immune response. This inflammatory pathway by sensing various pathogens and molecules from damaged cells and then activation of caspase-1 enzyme initiates inflammatory responses. Activated caspase-1 leads to the proteolytic cleavage of the pro-inflammatory cytokines, interleukin-1 beta (IL-1 beta) and interleukin-18 (IL-18), and also induction of an inflammatory programmed cell death termed pyroptosis. NLR family pyrin domain-containing 1 (NLRP1) and NLRP3 are the two best-characterized inflammasome members, and both basic and clinical research has reported their activation during epilepsy. This overview is intended to summarize the current literature concerning NLRP1 and NLRP3 inflammasome activation and epilepsy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available